Research programme: RNAi therapeutics - Arrowhead Pharmaceuticals

Drug Profile

Research programme: RNAi therapeutics - Arrowhead Pharmaceuticals

Alternative Names: ARC AMG1; ARC HIF2; ARC LPA; ARC-F12; ARO AAT; ARO ANG3; ARO APOC3; ARo Lung1; ARO-AMG1; ARO-F12; ARO-HBV; ARO-LPA; ARO-Lung1; RNAi ARC-LPA

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mirus Bio Corporation
  • Developer Arrowhead Pharmaceuticals; Roche Madison
  • Class Small interfering RNA
  • Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency; Cardiovascular disorders; Hepatitis B; Hereditary angioedema; Hypertriglyceridaemia; Liver cancer; Lung cancer; Renal cell carcinoma; Solid tumours; Thromboembolism
  • No development reported Hyperlipidaemia; Respiratory tract disorders

Most Recent Events

  • 14 Sep 2017 Preclinical trials in Lung cancer in USA (Inhalation)
  • 14 Sep 2017 Arrowhead Pharmaceuticals plans to file a clinical trial application (CTA) for Lung disorders in the fourth quarter of 2018 for ARO-Lung1
  • 14 Sep 2017 Arrowhead Pharmaceuticals plans to file a clinical trial application (CTA) for Alpha-1 antitrypsin deficiency for ARO-AAT in the first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top